Navigation Links
Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment

ST. PAUL, Minn., April 3 /PRNewswire/ -- Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 leading academic and private medical centers in the U.S. and Europe, will evaluate the safety and effectiveness of the LINX System in patients suffering from GERD despite medical therapy.

GERD is caused by a defective lower esophageal sphincter, a ring-like muscular valve that surrounds the esophagus. When defective, it allows abnormal reflux of stomach acids and bile into the esophagus. Approximately 19 million adults in the U.S. suffer on a daily basis from the symptoms of GERD. Medical therapy, such as the daily use of proton pump inhibitors (PPIs), may improve heartburn symptoms but it does not address the mechanically defective sphincter, allowing gastric reflux to continue. Chronic gastric reflux may lead to numerous complications including ulcerations and esophageal cancer. The incidence of esophageal cancer is rising at a faster rate than any other cancer in the U.S.

Robert Ganz, M.D. of Minnesota Gastroenterology and a Principal Investigator in the trial shared these comments, "Many people who suffer from GERD do not get complete relief of symptoms with drug therapy. The LINX System is intriguing because it may provide both symptom relief and correction of the physiologic defect."

The LINX Reflux Management System is intended to restore the normal barrier function in the esophagus for patients who suffer from GERD and is designed to be an outpatient, minimally invasive procedure. The device is implanted laparoscopically, with the patient likely to resume normal activities and diet at discharge. In addition to its therapeutic benefits, Torax Medical anticipates that the LINX System will have the potential to eliminate the burdens associated with lifelong drug therapy and the typical complications associated with conventional surgical repair.

Todd Berg, President and CEO of Torax Medical, considers the LINX System a promising advancement for the treatment of GERD, "We believe the simplest approach to treating GERD is to augment the body's existing sphincter so that it can function normally. Excellent clinical results were achieved in feasibility trials with the LINX System and we expect these positive clinical outcomes to continue in this Pivotal Trial".

To learn more about the study and to determine if you qualify as a candidate, visit or call 1-888-978-8391.

The LINX Reflux Management System is an investigational device and is limited by Federal U.S. law to investigational use only and is not available for sale.

About Torax Medical

Torax Medical Inc. is a privately held medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease. Its platform technology utilizes magnetic attraction forces to augment the body's sphincter anatomy. For more information, please visit

SOURCE Torax Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
3. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
4. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
6. Premier Research Expands its Medical Device Operations to the United States
7. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
8. Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
9. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
10. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):